MD-IPROOV
13.1.2021 01:02:32 CET | Business Wire | Press release
Mvine and iProov announce today their design for a simple, secure and widely recognized Covid-19 immunity and vaccination passport will now move into live testing. The Mvine-iProov passport enables a person’s test result or vaccination status to be registered and proved without disclosing their identity, and without the need for extensive new infrastructure.
With additional backing from Innovate UK, which initially funded the development of a successful working prototype, the Mvine-iProov passport will now be tested by Directors of Public Health within the National Health Service (NHS) in the UK. Mvine and iProov aim to complete two trials by 31 March 2021, giving Directors of Public Health across the country the confidence to deploy the passport at scale to benefit their local areas.
Crucially, the Mvine-iProov passport can be plugged into the NHS’ existing infrastructure, enabling it to meet the specific needs of local Directors of Public Health and any overarching national requirements. This flexibility ensures that areas in different tiers or levels of vaccination rollout can set appropriate policies and enforce them with confidence.
The Mvine-iProov passport has been developed quickly and cost-efficiently, with a total £75,000 investment from Innovate UK following a call for ideas in April 2020. It is expected this investment in UK innovation will help businesses and employees return to work, and enable families and friends to reconnect, more quickly and more responsibly than would otherwise be possible.
Frank Joshi, Director at Mvine, said: “Without the need for an extensive new infrastructure, the Directors of Public Health will learn how our innovation is used to promote public health and protect citizen privacy. Unlike some other digital solutions for Covid-19, this technology reduces the burden on frontline services and cost-effectively assures a secure and safe way to enable the return to work, return to school and return to the kind of life that people want to lead .”
Andrew Bud, CEO at iProov, said: “Ensuring consumer trust, security and privacy is essential to the success of projects in this space. iProov enables all three. Our Genuine Presence Assurance technology secures the link between the citizen and Mvine’s test status solution in this project, which we think can make an important contribution to forming the national response to the COVID-19 crisis.”
ENDS
About iProov
Founded in 2012, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to remotely verify customer identity. Used for onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), GovTech Singapore, Eurostar, Rabobank, ING, and others. iProov’s unique patented technology provides Genuine Presence Assurance, ensuring that an online customer is the right person, a real person, and authenticating right now. This protects against spoof attacks from photos, videos, masks and the emerging threat of deepfakes. iProov was recognized as the 5th fastest growing technology company in the UK in the Deloitte 2020 UK Technology Fast 50 and was also named a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com
About Mvine
Mvine Limited is a British deep tech company delivering next generation platforms that power the digital economy. It is perhaps best known for its work in providing cyber-secure collaboration portals, in use in the financial services sector as virtual deal rooms and in other industries as procurement portals and as diversity/equality portals. The company has also pursued identity management and its technology is in use in the telecoms sector for federated authentication and in other industries for single sign on identity, authentication and authorization. www.mvine.com
About Innovate UK
Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth. We fund business and research collaborations to accelerate innovation and drive business investment into R&D. Our support is available to businesses across all economic sectors, value chains and UK regions. Innovate UK is part of UK Research and Innovation. For more information visit www.innovateuk.ukri.org
Fact Checking
The UK government announcement on 20 May 2020 to expand the funding envelope from £20 million to £40 million meant 800 funding awards could be made. The original announcement was made on 3 April 2020 by BEIS, Innovate UK and Amanda Solloway MP. The competition opened Friday 3 April 2020 and closed Friday 17 April 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112006124/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cardiac Dimensions® Announces Three Major Publications Demonstrating Long-Term Durability, Real-World Performance, and Broad Patient Benefit of the Carillon Mitral Contour System®8.7.2026 16:05:00 CEST | Press release
New data highlight multi-center 5-year durability, 10-year survival, and the largest single-center experience across both HFrEF and HFpEF patients with functional mitral regurgitation Cardiac Dimensions, a leader in transcatheter therapies for heart failure, today announced the publication of three major manuscripts that together form the most comprehensive evidence base ever assembled for transcatheter indirect mitral annuloplasty. These publications span a five-year multi-center commercial registry, the largest single-center experience across both preserved and reduced ejection fraction, and long-term survival results through ten years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707656796/en/ Carillon Mitral Contour System® The Carillon Mitral Contour System is the only commercially available indirect mitral annuloplasty device, designed to treat a broad and expanding population of patients living with functional mi
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom